GUMDROP : JHMI J1106 A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel aka TAK-700 Plus Prednisone With Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Created by Channing Paller, last modified on Apr 14, 2012

Description:

This trial measures the effect of TAK-700 on overall survival of castrate-resistant prostate cancer patients who have radiographic evidence of metastases; progressive disease based on PSA and/or radiographic criteria; testosterone < 50 ng/dL; screening PSA = 2 ng/mL; and NO prior orteronel, ketoconazole, aminoglutethimide, or abiraterone.

Link:

http://clinicaltrials.gov/ct2/show/NCT01193257

Site:

Johns Hopkins Hospital

Principal Investigator:

Hans Hammers, M.D.